A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b.

Trial Profile

A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2014

At a glance

  • Drugs Odalasvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2014 Results were presented at the 23rd Asian Pacific Association for the Study of the Liver (APASL) Conference 2014 according to an Achillion Pharmaceuticals media release.
    • 24 Dec 2013 Status changed from active, no longer recruiting to completed as reported in ClinicalTrials.gov record.
    • 23 Apr 2013 Interim results from eight patients with IL28B CC subtype published in an Achillion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top